Opin vísindi

Defining new reference intervals for serum free light chains in individuals with chronic kidney disease : Results of the iStopMM study

Skoða venjulega færslu

dc.contributor University of Iceland
dc.contributor Landspitali - The National University Hospital of Iceland
dc.contributor.author Long, Þórir Einarsson
dc.contributor.author Indriðason, Ólafur Skúli
dc.contributor.author Pálsson, Runólfur
dc.contributor.author Rögnvaldsson, Sæmundur
dc.contributor.author Löve, Þorvarður Jón
dc.contributor.author Thorsteinsdóttir, Sigrún
dc.contributor.author Sverrisdóttir, Ingigerður S
dc.contributor.author Viðarsson, Brynjar
dc.contributor.author Önundarson, Páll Torfi
dc.contributor.author Agnarsson, Bjarni Agnar
dc.contributor.author Sigurðardóttir, Margrét
dc.contributor.author Þorsteinsdóttir, Ingunn
dc.contributor.author Ólafsson, Ísleifur
dc.contributor.author Thordardottir, Asdis Rosa
dc.contributor.author Eyþórsson, Elías Sæbjörn
dc.contributor.author Jónsson, Ásbjörn
dc.contributor.author Gíslason, Gauti Kjartan
dc.contributor.author Ólafsson, Andri
dc.contributor.author Steingrímsdóttir, Hlíf
dc.contributor.author Hultcrantz, Malin
dc.contributor.author Durie, Brian G.M.
dc.contributor.author Harding, Stephen
dc.contributor.author Landgren, Ola
dc.contributor.author Kristinsson, Sigurður Yngvi
dc.date.accessioned 2022-09-27T01:02:38Z
dc.date.available 2022-09-27T01:02:38Z
dc.date.issued 2022-09-14
dc.identifier.citation Long , Þ E , Indriðason , Ó S , Pálsson , R , Rögnvaldsson , S , Löve , Þ J , Thorsteinsdóttir , S , Sverrisdóttir , I S , Viðarsson , B , Önundarson , P T , Agnarsson , B A , Sigurðardóttir , M , Þorsteinsdóttir , I , Ólafsson , Í , Thordardottir , A R , Eyþórsson , E S , Jónsson , Á , Gíslason , G K , Ólafsson , A , Steingrímsdóttir , H , Hultcrantz , M , Durie , B G M , Harding , S , Landgren , O & Kristinsson , S Y 2022 , ' Defining new reference intervals for serum free light chains in individuals with chronic kidney disease : Results of the iStopMM study ' , Blood Cancer Journal , vol. 12 , no. 9 , 133 , pp. 133 . https://doi.org/10.1038/s41408-022-00732-3
dc.identifier.issn 2044-5385
dc.identifier.other 60192321
dc.identifier.other 6890b99d-f5c6-44a2-848b-c3d0bea04d28
dc.identifier.other 85137808095
dc.identifier.other 36100605
dc.identifier.uri https://hdl.handle.net/20.500.11815/3484
dc.description Funding Information: Dr. Landgren has received grant support from: NCI/NIH, FDA, LLS, Rising Tide Foundation, Memorial Sloan Kettering Cancer Center, MMRF, IMF, Paula, and Rodger Riney Foundation, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; has received honoraria for scientific talks/participated in advisory boards for: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and served on Independent Data Monitoring Committees (IDMC) for international randomized trials by: Takeda, Merck, Janssen, Theradex. Dr. Hultcrantz has recevied grant support from GSK, Amgen, Daiichi Sankyo, Cosette Pharmaceuticals, and has received honoraria for scientific talks/participated in advisory boards for BMS, Curio Science, and Intellisphere LLC. All other authors declare no potential conflicts of interest. Funding Information: Dr. Kristinsson has received research funding from International Myeloma Foundation, European Research Council, Icelandic Center for Research (Rannís), Amgen, Celgene. Dr. Long has received research funding from the Icelandic Center for Research (Rannís). Dr. Landgren thanks Sylvester Comprehensive Cancer Center Core Grant (P30 CA240139) and Paula and Rodger Riney Foundation for support of his research. Dr. Hultcrantz thanks the Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748). The iStopMM study is funded by the Black Swan Research Initiative by the International Myeloma Foundation, the European Research Council, and the Icelandic Center for Research. Screening tests for the iStopMM study are performed by The Binding Site Ltd. Birmingham, UK. Additional funding is provided by the University of Iceland, Landspitali–The National University Hospital, and the Icelandic Cancer Society. Funding Information: Dr. Kristinsson has received research funding from International Myeloma Foundation, European Research Council, Icelandic Center for Research (Rannís), Amgen, Celgene. Dr. Long has received research funding from the Icelandic Center for Research (Rannís). Dr. Landgren thanks Sylvester Comprehensive Cancer Center Core Grant (P30 CA240139) and Paula and Rodger Riney Foundation for support of his research. Dr. Hultcrantz thanks the Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748). The iStopMM study is funded by the Black Swan Research Initiative by the International Myeloma Foundation, the European Research Council, and the Icelandic Center for Research. Screening tests for the iStopMM study are performed by The Binding Site Ltd. Birmingham, UK. Additional funding is provided by the University of Iceland, Landspitali–The National University Hospital, and the Icelandic Cancer Society. Publisher Copyright: © 2022, The Author(s).
dc.description.abstract Serum free light chain (FLC) concentration is greatly affected by kidney function. Using a large prospective population-based cohort, we aimed to establish a reference interval for FLCs in persons with chronic kidney disease (CKD). A total of 75422 participants of the iStopMM study were screened with serum FLC, serum protein electrophoresis and immunofixation. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine. Central 99% reference intervals were determined, and 95% confidence intervals calculated. Included were 6461 (12%) participants with measured FLCs, eGFR < 60 mL/min/1.73 m 2, not receiving renal replacement therapy, and without evidence of monoclonality. Using current reference intervals, 60% and 21% had kappa and lambda FLC values outside the normal range. The FLC ratio was outside standard reference interval (0.26-1.65) in 9% of participants and outside current kidney reference interval (0.37-3.10) in 0.7%. New reference intervals for FLC and FLC ratio were established. New reference intervals for the FLC ratio were 0.46-2.62, 0.48-3.38, and 0.54-3.30 for eGFR 45-59, 30-44, and < 30 mL/min/1.73 m 2 groups, respectively. The crude prevalence of LC-MGUS in CKD patients was 0.5%. We conclude that current reference intervals for FLC and FLC ratio are inaccurate in CKD patients and propose new eGFR based reference intervals to be implemented.
dc.format.extent 1
dc.format.extent 1364270
dc.format.extent 133
dc.language.iso en
dc.relation.ispartofseries Blood Cancer Journal; 12(9)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Lífefna- og sameindalíffræði
dc.subject Blóðlæknisfræði
dc.subject Myndgreining (læknisfræði)
dc.subject Nýrnalæknisfræði
dc.subject Meinafræði
dc.subject Gigtarlæknisfræði
dc.subject Humans
dc.subject Immunoglobulin Light Chains
dc.subject Immunoglobulin lambda-Chains
dc.subject Prospective Studies
dc.subject Reference Values
dc.subject Renal Insufficiency, Chronic/diagnosis
dc.subject Hematology
dc.subject Oncology
dc.title Defining new reference intervals for serum free light chains in individuals with chronic kidney disease : Results of the iStopMM study
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1038/s41408-022-00732-3
dc.relation.url http://www.scopus.com/inward/record.url?scp=85137808095&partnerID=8YFLogxK
dc.contributor.department Internal Medicine and Emergency Services
dc.contributor.department Other departments
dc.contributor.department Faculty of Medicine
dc.contributor.department Clinical Laboratory Services, Diagnostics and Blood Bank
dc.contributor.department Office of Division of Clinical Services II
dc.contributor.department Cancer Center


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu